Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOASIS neoadjuvant pan-tumor immunotherapy basket study
NL-OMON59871Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of botensilimab and balstilimab in colorectal cancer (CRC), rectal cancer, esophageal cancer and 13 more (6 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Major pathologic response rate and Complete or near-complete clinical response rate in dMMR rectal organ preservation cohort. Started Jan 2024; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)rectal canceresophageal cancergastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON59871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59871.